When the clinical trial ecosystem is under pressure on multiple fronts, clinical trial sites must be able to support complex, diverse trial designs, reach underrepresented populations, and ensure seamless clinical research participant experience.
Clinical trial protocols have grown dramatically in complexity and scale. According to the Tufts Center for the Study of Drug Development, the average number of endpoints nearly doubled between 2010 and 2020, with the total data points collected per study tripling or more. Industry reports show that a Phase III trial now often generates more than 3.5 million discrete data points – a reflection of increasingly complex protocols, frequent amendments and expanded adaptive designs. This data complexity has been directly linked to reduced recruitment speed, more frequent deviations and higher rates of trial amendments.
When the clinical trial ecosystem is under pressure on multiple fronts, clinical trial sites must be able to support complex, diverse trial designs, reach underrepresented populations, and ensure seamless clinical research participant experience. Explore how sites can align with the needs of the sponsor in this challenging environment by reading this new white paper.
Offered Free by: Trialmed
See All Resources from: Trialmed
